Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01070810 · ClinicalTrials.gov registry record · Phase 1
Thiamine as a Metabolic Resuscitator in Septic Shock
A Phase 1 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
NCT01070810 is a Phase 1 study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 88 participants.
The verdict
NCT01070810, a Phase 1 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
Study Summary
The major goal of this project is to determine whether the use of thiamine in patients with septic shock will result in attenuation of lactic acidosis and a more rapid reversal of shock.
Interventions
- DRUG Thiamine
- DRUG D5W
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2010-02 |
| Est. Completion | 2014-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01070810
The ClinicalTrials.gov registry entry for NCT01070810 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Thiamine is the first listed.
NCT01070810 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01070810 about?
NCT01070810 is a clinical study titled "Thiamine as a Metabolic Resuscitator in Septic Shock". The major goal of this project is to determine whether the use of thiamine in patients with septic shock will result in attenuation of lactic acidosis and a more rapid reversal of shock.
What is the current status of trial NCT01070810?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2010-02. Estimated completion is 2014-11.
What interventions are being tested in trial NCT01070810?
The interventions under investigation include: Thiamine (DRUG), D5W (DRUG).
Who is sponsoring clinical trial NCT01070810?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.